OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Curing Ourselves of Toxic Positivity for Hospital-at-Home	257
Wearable Remote Patient Monitoring Devices	133
Reply	115
Reply	106
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	102
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	101
Long-Term Effects of Sotatercept on Right Ventricular Function	93
Developing a System for Best Performance for Cardiac Transplantation	89
Reply	88
Reply	84
Editorial Board	83
Full issue PDF	81
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	76
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	75
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure	73
Opportunities for Change in Home Health Care in Heart Failure	72
Correction	70
Associations Between Urinary Metal Levels and Incident Heart Failure	70
Unique Proteomic Signatures in Human Anthracycline-Induced Dilated Cardiomyopathy	70
Clinical Implications of the P.V142I TTR Variant	67
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	65
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	65
Eating to Prevent Both Heart and Planetary Failure	64
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	63
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	61

Revisiting ICD Therapy for Primary Prevention	59
Contemporary Trends in Heart Failure Mortality	58
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	56
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	56
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	56
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	56
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	54
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	53
Predictors of Incident Heart Failure Diagnosis Setting	49
Challenges Addressing Prognosis in Advanced Heart Failure	47
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	47
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	45
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	45
Heart Failure With Preserved Ejection Fraction	44
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	44
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	43
NT-proBNP	43
Body Composition and Survival in Patients With Heart Failure	43
Framework for Analytical Validation of DHT-Based Actigraphy and Signal Measures in HF Trials	43
Genetically Proxied Interleukin-6 Signaling Inhibition and Heart Failure Risk	42
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	42
GDF-15 in Cardiovascular Disease	42
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	42
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	41
Prognosis for Acute Myocarditis	41
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	41
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	41
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	40
Compensation Models in Heart Failure	40
Plasma Aldosterone Measurement to Guide Prevention and Treatment of Heart Failure in Black Adults With Hypertension	40
Full Issue PDF	39
From Dispensing Pills to Building Pillars	39
Racial and Genetic Differences	38
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	38
A Woman's Work Is Never Done	37
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	37
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	37
Thank You for the Privilege	37
Heart Failure in Women	36
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	34
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	34
STRONG-HF	34
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	33
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	32
Advanced Heart Failure in the Cardiac Intensive Care Unit	32
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	32
Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension	32
Reply	31
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction	31
The Path Toward a More Equitable Transplant System	31

Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	30
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	30
High NT-proBNP in Heart Failure	30
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	30
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	29
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	29
Reply	29
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	29
Facts and Fallacies of Body Composition Analysis in Heart Failure	29
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	28
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	28
Risk Factors and Temporal Trends of Maternal Heart Failure	27
Therapeutic Options in Ambulatory Advanced Heart Failure	27
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	27
Upper Body Hypoxemia During ECMELLA	27
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	27
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	27
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	26
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	26
Policy Changes for Progress	26
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	26
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	26
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	26
Understanding and Investigating Sex-Based Differences in Heart Transplantation	26
Smoking Cessation Reduces the Risk of Heart Failure	25
Management of Heart Failure–Related Cardiogenic Shock	25
Rethinking Lifelong Management of Heart Failure Care in Young Adults	25
Obesity and Weight Loss Strategies for Patients With Heart Failure	25
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022	25
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	25
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	25
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	24
Critical Importance of Genetic Screening in Family Members	24
Diabetes Therapy With SGLT2i After Heart Transplant	24
Instructions for Authors	24
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	24
Jump Starting the Heart	24
Reevaluating Growth Hormone Therapy in HFrEF	24
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	24
Tafamidis in Octogenarians	24
To Infinity and Beyond	24
Full issue PDF	24
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	24
Every Journey Needs a Guide	24
Setting the Diagnosis of Heart Failure	24
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	23
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	23
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	23
Moving From Prompts to Praxis With Remote Monitoring	23
Beyond Coronary Atherosclerosis	23
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	23
Full issue PDF	23
Venting the Venous Circulation	23
Redefining Pre–Heart Failure With Cardiac Biomarkers	23
Isolating Noise From Signals in the Air	22
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	22
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	22
Editorial Board	22
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	22
Secondary Mitral Regurgitation Trajectories and Prognosis With Intensification of Guideline-Directed Medical Therapy in Heart Failure	22
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	22
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	22
Expanded Definition of Worsening Heart Failure	22
From Better Models to Better Care	22
Illuminating a Hidden Risk	22
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	21
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	21
Severe Myocarditis Increase in Children Associated With Parvovirus B19 Infection	21
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	21
Unreliable HFpEF Diagnosis by H2FPEF in AF	21
Treatment of Obesity in Heart Failure	21
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	21
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	20
Global Heart Failure Trends in Young Adults	20
All That Glitters Is Not Gold	20
Full Issue PDF	20
HFpEF Scores	20
Bereavement and Mortality in Heart Failure	19
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	19
Reply	19

Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	19
Istaroxime in HFpEF	19
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	18
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	18
Diet and Heart Failure	18
The Link Between Heart Failure and Neurodegeneration	18
Deactivation of Left Ventricular Assist Devices at the End of Life	18
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	18
Physical Activity Trajectories Preceding Incident Heart Failure	18
Correction	18
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	18
Impact of Female Sex on Cardiogenic Shock Outcomes	18
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure	17
Artificial Intelligence to Extract Structured Details From Unstructured Medical Records in a Global Heart Failure Trial	17
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	17
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	17
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	17
REPLY	17
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	17
Articulating the JACC Journals’ Direction in Times of Global Change	17
Mechanically Reducing Cardiac Preload With the preCARDIA System in Acutely Decompensated Heart Failure	17
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	17
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	17
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	17
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	17
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	16
Reply	16
Correction	16
Reducing Pediatric Heart Failure Readmissions	16
The Enigma of Natriuretic Peptides	16
Navigating the Global Burden of Pulmonary Arterial Hypertension	16
Shedding Light on the Darkness of MYH7 Cardiomyopathies	16
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	16
Reply	16
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	16
Full issue PDF	15
Medication Optimization Clinic	15
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	15
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	15
Thin Evidence, Heavy Need	15
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	15
Targeting Inflammation in Heart Failure Prevention	15
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	15
Low Serum Ferritin Might Predict Incident Heart Failure	15
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	15
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	14
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	14
Exercise-Induced Versus Resting Left Atrial Hypertension	14
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	14
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	14
Coronary Artery Disease Is Still a Major Cause of Heart Failure	14
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	14
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	14
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	14
Better 3 Hours Too Soon Than 1 Minute Late	14
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	14
Reflections on Early Rehabilitation in Acute Heart Failure	14
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	14
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	14
Contemporary American and European Guidelines for Heart Failure Management	14
Aging in Heart Failure	14
Full issue PDF	14
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	13
REPLY	13
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	13
The HeartMate 3 Risk Score	13
Redefining Boundaries in Heart Failure Care	13
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	13
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	13
Information for Authors	13
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	13
Pregnancy as a Sentinel Event	13
Reply	13
Persistent Disparities in Heart Failure	12
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	12
Correction	12
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	12
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	12
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	12
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	12
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	12
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	12
Can Sensor Implantation Alone Reduce Heart Failure Hospitalizations Without Need for Structured Management Based on its Data?	12
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	12
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	12
Officers Page	12
Iron Deficiency Definition and Management in Patients With Heart Failure	12
BMI in HFpEF	12
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	12
From Fuel to Flow	12
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	11
Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction	11
“Pharmacoequity” in Heart Failure Treatment	11
But Is All Post-Transplant Lymphoproliferative Disorder Created Equal?	11
Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure	11